Gynecologic Cancer Clinical Trials
The Hanjani Institute for Gynecologic Oncology offers patients access to a wide array of clinical trials for gynecologic oncology. Our physicians are primary principal investigators for the Gynecologic Oncology Group (GOG) of the National Cancer Institute (NCI). This active participation in investigative medicine means that our patients may take part in studies looking at promising new advances while remaining close to home, family and work.
Other available clinical trials include those designed by our physicians or in collaboration with other institutions and industry. This research aims to advance knowledge and treatment options for gynecologic cancers that are some of the most difficult to treat.
An average of 40 clinical trials for gynecologic cancer may be in progress here at any given time. The wide range of new treatment modalities being investigated includes the use of:
- chemotherapy to make cancer more responsive to radiation
- biologic response modifiers to stimulate the immune system to fight cancer cells
- anti-angiogenesis agents, which may stop cancer growth by blocking the formation of new blood vessels
- newly developed vaccines for after a second remission of cancer
Our director of clinical research, a Ph.D. nurse practitioner, works with a team of three specialized oncology research nurses to provide expert care to gynecologic cancer patients enrolled in clinical trials. These professionals manage all aspects of cancer treatment with an emphasis on quality of life.
To find out the latest information about gynecologic cancer clinical trials at the Hanjani Institute for Gynecologic Oncology:
Discuss all options with your gynecologic oncologist and treatment plan team.
The gynecologic cancer nurse navigators also can answer questions about clinical trials at 215-481-4670 and email@example.com, firstname.lastname@example.org or email@example.com
Learn more about our gynecologic cancer care: